US Physical Therapy
| CURRENT PRICE | PROBABILITY-WEIGHTED FAIR VALUE | FAIR VALUE RANGE |
|---|---|---|
| $60 | ~$72 | $48 – $95 |
| May 2026 | Bull 25% / Base 50% / Bear 25% | ~20% upside |
Verdict: USPH delivered Q1 2026 record revenue of $198.3M (+7.9%) but earnings were dragged by a $2M loss on earn-out fair value (vs. $4.8M gain prior-year). Adjusted EBITDA guidance was reaffirmed at $102-106M[1]. The stock has de-rated meaningfully (52-week range $58-$94) on reimbursement pressure concerns. At ~21x forward P/E for a defensive healthcare services business with steady cash flow and acquisition optionality, the asymmetry favors upside if reimbursement headwinds stabilize.
CURRENT SNAPSHOT
| Metric | Value | Notes / Source |
|---|---|---|
| Stock price | ~$60 | 52w range $58-$94 [2] |
| Q1 2026 revenue | $198.3M (+7.9%) | Record quarter [1] |
| Q1 2026 net income | $5.0M | Hurt by $2M earn-out loss [1] |
| Q1 2026 EPS | ($0.12) | vs $0.80 prior year [1] |
| FY26 Adj EBITDA guide | $102M – $106M | Reaffirmed [1] |
| Forward P/E (Yahoo) | 21.2x | Other source 29.7x [3] |
BULL / BASE / BEAR SCENARIOS
| Scenario (weight) | Assumptions | Fair Value |
|---|---|---|
| Bull (25%) | Medicare reimbursement clarity, acquisition pipeline executes, multiple expands to 30x | $95 |
| Base (50%) | Hit guide ($104M EBITDA), modest acquisitions, multiple holds at 23x | $72 |
| Bear (25%) | Medicare cuts deeper, labor cost pressure, multiple compresses to 17x | $48 |
| Probability-weighted | Defensive healthcare services compounder; reimbursement risk caps upside, but cash flow is steady. | ~$72 |
Key Risks
- Medicare reimbursement: Annual PT reimbursement updates; 2026 saw further compression in some categories.
- PT labor costs: PT wage inflation outpacing revenue; staffing remains tight.
- Earn-out volatility: Acquisition earn-outs introduce P&L noise.
- Acquisition execution: Growth model depends on rolling up local PT practices; multiples bid up.
What Would Change Our View
- Upside: CMS reimbursement clarity, accretive M&A, IIP segment expansion.
- Downside: Reimbursement cuts deepen, labor costs spike, M&A pipeline slows.
Sources
[1] https://www.sec.gov/Archives/edgar/data/0000885978/000088597826000019/ex99-1.htm
[2] https://finance.yahoo.com/quote/USPH/
[3] https://stockanalysis.com/stocks/usph/statistics/
Disclaimer
This output is for informational and research-assistance purposes only. It does not constitute investment, legal, tax, accounting, or other professional advice, and it is not a recommendation to buy, sell, or hold any security. Verify material facts independently and consult qualified advisors before making decisions.